Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04324645
Other study ID # 202003007
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 3, 2020
Est. completion date March 13, 2022

Study information

Verified date April 2022
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study seeks to achieve two aims: - To assess the implementation of Noona software for continuous symptom monitoring for a diverse population of patients with thoracic malignancies who are undergoing radiation and - To validate remote collection of standardized PRO measures using Noona software.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 13, 2022
Est. primary completion date March 13, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biopsy confirmed cancer. Radiographically apparent (i.e. not histologically or cytologically confirmed) malignancy of the thorax is allowed. - Currently planning to receive radiotherapy with or without chemotherapy for greater than one fraction. - Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). - Age 18 years or older Exclusion Criteria: -Unable to reliably access and use a device compatible with Noona software.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Noona Software
Enrolled patients will be provided with login information for their Noona account. Patients will log in to the Noona symptom monitoring system using their own computer hardware. Any type of personal computer or compatible mobile device will be allowed (i.e. iPhone, Android phone). Patients will be able to access the Noona system from any internet access point and will be provided with the hospital/clinic public WiFi information.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine Varian Medical Systems

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of invited symptom reports completed during the study period Treatment through 90 days of follow-up (estimated to be 5 months)
Primary Percentage of questions completed within each invited symptom report Treatment through 90 days of follow-up (estimated to be 5 months)
Secondary Patient reported outcomes as measured by EORTC QLQ-C30 It includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Patients respond on a four-point scale from "not at all" to "very much" for most items. Most items use a "past week" recall period. Raw scores are linearly converted to a 0-100 scale with higher scores reflecting higher levels of function and higher levels of symptom burden. Baseline, within 1 week of completing therapy and at 90-day follow-up
Secondary Patient reported outcomes as measured by NCCN Distress Thermometer Measures distress experienced during the past week. 10 = extreme distress and 0=no distress Baseline, within 1 week of completing therapy and at 90-day follow-up
See also
  Status Clinical Trial Phase
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Completed NCT01635270 - Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma Phase 2
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Recruiting NCT03731130 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT05721053 - Improving Outcomes for Older Adults Undergoing Radiation Therapy
Active, not recruiting NCT04764227 - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Phase 2
Not yet recruiting NCT05821452 - Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma Phase 2
Recruiting NCT05335148 - Study to Evaluate the Safety of Colchicine Phase 1
Recruiting NCT04362306 - Radiation Oncology Patient Medical Physics Intervention Study N/A
Completed NCT01917890 - Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer N/A
Not yet recruiting NCT05648253 - Hyivy Device in Post-radiation Patients N/A
Completed NCT03235427 - The CAROLE (CArdiac Related Oncologic Late Effects) Study
Recruiting NCT03142425 - Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy
Recruiting NCT05406063 - Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases N/A
Recruiting NCT03071289 - A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer Phase 3
Recruiting NCT03213925 - Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer Phase 2
Recruiting NCT06128863 - Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Phase 2
Recruiting NCT05351294 - Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet Phase 3
Recruiting NCT05817201 - Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Phase 2/Phase 3